KN5504

KN5504 is a chimeric antigen receptor-engineered natural killer (CAR-NK) cell therapy being developed by Rui Therapeutics (Shenzhen Enrui Kainuo Biotechnology). It is part of the company's proprietary CAR-NK technology platform, which focuses on developing 'First-in-Class' cell therapies. The treatment involves the genetic modification of NK cells to express a CAR, enabling them to specifically target and eliminate cells expressing a particular antigen. As of early 2024, KN5504 is in the early research and development (preclinical) stage, with its specific molecular target and primary disease indication remaining undisclosed by the developer.